Diabetes Mellitus Clinical Trial
Official title:
Evaluation of Platelet Rich Fibrin Growth Factors (PRF) in Type 2 Diabetic Patients With Chronic Periodontitis
Diabetic patients may show different release of growth factors when microvascular complications such as; retinopathy or periodontitis are seen. Diabetes have an adverse effect on periodontal health and periodontal infection have an adverse effect on glycemic control and incidence of diabetes complications. Therefore, the investigators hypothesize that growth factors levels releasing from platelet rich fibrin (PRF) in diabetes mellitus (DM) may be decrease because of periodontitis is considered to be the sixth microvascular complication of diabetes or diabetes may have inductive effect on PRF growth factors levels in periodontal disease. Determination of PRF growth factors levels may be beneficial to treatment of diabetic patient with periodontal disease by using PRF.
The aim of the investigators study was to evaluate levels of platelet derived growth
factor-AB (PDGF-AB), vascular endothelial growth factor ( VEGF),transforming growth
factor-beta1 and beta 2 (TGF-β1 and β2), basic-Fibroblast growth factor (b-FGF), insulin
like growth factor-1 ( IGF-1) in type 2 diabetic (T2DM) patients with chronic periodontitis.
This study consisted of 80 subjects; 20 patients were T2DM with periodontally healthy
(DM-CTRL), 20 patients were T2DM with chronic periodontitis (DM-CP ), 20 patients were
systemically healthy with chronic periodontitis (CP; ), 20 subjects were systemically and
periodontally healthy (CTRL).
Subjects were clinically evaluated with regards to the plaque index (PI), gingival index
(GI), probing pockets depth (PD), clinical attachment level (CAL), bleeding on probing (BOP)
recorded at six sites per tooth (disto-facial, mid-facial, mesio-facial, mesio-lingual,
disto-lingual and mid-lingual) using a periodontal Goldman/Fox Williams probe calibrated in
millimeters.
PRF was prepared without biochemical manipulation of blood. Intravenous blood from each
patient was collected in 10 ml sterile tubes without anticoagulant by venipuncture of
antecubital vein. Immediately test tubes were centrifuged using a centrifugation machine (
Electro.mag M 815 P Laboratory Centrifuge ; Istanbul, Turkey) at 2700 rpm ( approximately
700g ) for 12 min . The centrifuged blood presented with a structured fibrin clot in the
middle of the tube just between the red corpuscles at the bottom and acellular plasma at the
top. PRF was easily separated from the red corpuscule base using steril scissors and
inserted into steril tubes. The tubes were put on a shaker and agitated gently. After 5
minutes, the tubes were vortexed to form a PRF membrane and the volume of releasate was
measured and the releasate returned into the tube. The tubes were further agitated gently.
Samples were taken at 5th minute and immediately centrifuged at 5000rpm for 15 minutes
(Electro.mag M 815 P Laboratory Centrifuge ; Istanbul, Turkey) to pellet any residual blood
cells , and were stored at -80 centigrade degree for subsequent assays.
Samples were assayed by using enzyme-linked immunosorbent assay (ELISA) with an ELX 800 G
ELISA device (BIO-TEC Instruments, Winooski, USA). The following ELISA kits were used in
this study: b-FGF, TGF-β2 and IGF 1 (Assay Biotechnology Company, CA, USA); PDGF-AB, VEGF
and TGF-β1 (Boster Biological Technology, CA, USA).
Statistical analysis was performed using a commercially available software (SPSS 15.0; SPSS
Inc., Chicago, IL). The Shapiro-Wilk test was used to investigate whether the data were
normally distributed. When normal distribution with equal variances was assumed in PDGF-AB,
VEGF, TGF-β1, variables were compared using one-way analysis of variance (ANOVA) with
Bonferroni post hoc test. If the assumption of normality failed, comparisons of the age,
TGF-β2, b-FGF, IGF-1, HbA1c, fasting blood glucose, postprandial blood glucose, full-mouth
PD, CAL, GI, PI and BOP were tested using the Kruskal-Wallis non-parametric test followed by
post-hoc group comparisons with the Bonferroni-adjusted Mann-Whitney U test.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |